Clinical systemic lupeol administration for canine oral malignant melanoma

Yokoe,Inoru; Azuma,Kazuo; Hata,Keishi; Mukaiyama,Toshiyuki; Goto,Takahiro; Tsuka,Takeshi; Imagawa,Tomohiro; Itoh,Norihiko; Murahata,Yusuke; Osaki,Tomohiro; Minami,Saburo; Okamoto,Yoshiharu

doi:10.3892/mco.2014.450

Clinical systemic lupeol administration for canine oral malignant melanoma

Authors:
- Inoru Yokoe
- Kazuo Azuma
- Keishi Hata
- Toshiyuki Mukaiyama
- Takahiro Goto
- Takeshi Tsuka
- Tomohiro Imagawa
- Norihiko Itoh
- Yusuke Murahata
- Tomohiro Osaki
- Saburo Minami
- Yoshiharu Okamoto
View Affiliations

Affiliations: School of Veterinary Medicine, Faculty of Agriculture, Tottori University, Tottori 680‑8553, Japan, Institute for Food and Brewing, Akita Prefectural Agricultural, Forestry and Fisheries Research Center, Akita 010‑1623, Japan, Sakamoto Bio Co., Ltd., Yuuwa‑Memeki, Akita 010‑1233, Japan
Published online on: October 30, 2014 https://doi.org/10.3892/mco.2014.450
Pages: 89-92

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Canine oral malignant melanoma (COMM) is the most aggressive malignant tumor in dogs. Lupeol is a triterpene extracted from various fruits and vegetables that reportedly inhibits melanoma cell proliferation in vitro and in vivo. In this study, the efficacy of subcutaneous lupeol for spontaneous COMM was evaluated. A total of 11 dogs (3, 5 and 3 dogs diagnosed with clinical stage I, II and III melanoma, respectively) were evaluated. Subcutaneous lupeol (10 mg/kg) was administered postoperatively at various time points to treat these 11 COMM cases. of the 11 subjects, 7 exhibited no local recurrence 180 days postoperatively and no severe adverse effects were observed in any of the cases. Furthermore, no distant metastasis was observed during the experimental period. Therefore, systemic lupeol may prevent local tumor progression and distant metastasis and may be a novel adjuvant treatment for the treatment of COMM.

View Figures

View References

1	Smith SH, Goldschmidt MH and McManus PM: A comparative review of melanocytic neoplasms. Vet Pathol. 39:651–678. 2002. View Article : Google Scholar : PubMed/NCBI
2	Bergman PJ: Canine oral melanoma. Clin Tech Small Anim Pract. 22:55–60. 2007. View Article : Google Scholar
3	Bateman KE, Catton PA, Pennock PW and Kruth SA: 0-7-21 radiation therapy for the treatment of canine oral melanoma. J Vet Intern Med. 8:267–272. 1994. View Article : Google Scholar : PubMed/NCBI
4	Blackwood L and Dobson JM: Radiotherapy of oral malignant melanomas in dogs. J Am Vet Med Assoc. 209:98–102. 1996.PubMed/NCBI
5	Proulx DR, Ruslander DM, Dodge RK, Hauck ML, Williams LE, Horn B, Price GS and Thrall DE: A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Vet Radiol Ultrasound. 44:352–359. 2003. View Article : Google Scholar : PubMed/NCBI
6	Rassnick KM, Ruslander DM, Cotter SM, Al-Sarraf R, Bruyette DS, Gamblin RM, Meleo KA and Moore AS: Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989–2000). J Am Vet Med Assoc. 218:1444–1448. 1996.PubMed/NCBI
7	Murphy S, Hayes AM, Blackwood L, Maglennon G, Pattinson H and Sparkes AH: Oral malignant melanoma - the effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapy. Vet Comp Oncol. 3:222–229. 2005. View Article : Google Scholar
8	Dank G, Rassnick KM, Sokolovsky Y, Garrett LD, Post GS, Kitchell BE, Sellon RK, Kleiter M, Northrup N and Segev G: Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision. Vet Comp Oncol. 12:78–84. 2014. View Article : Google Scholar : PubMed/NCBI
9	Freeman KP, Hahn KA, Harris FD and King GK: Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987–1997). J Vet Intern Med. 17:96–101. 2003.PubMed/NCBI
10	Saleem M, Kaur S, Kweon MH, Adhami VM, Afaq F and Mukhtar H: Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway. Carcinogenesis. 26:1956–1964. 2005. View Article : Google Scholar
11	Chaturvedi PK, Bhui K and Shukla Y: Lupeol: connotations for chemoprevention. Cancer Lett. 263:1–13. 2008. View Article : Google Scholar : PubMed/NCBI
12	Saleem M: Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Lett. 285:109–115. 2009. View Article : Google Scholar : PubMed/NCBI
13	Saleem M, Maddodi N, Abu Zaid M, Khan N, bin Hafeez B, Asim M, Suh Y, Yun JM, Setaluri V and Mukhtar H: Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin Cancer Res. 14:2119–2127. 2008. View Article : Google Scholar : PubMed/NCBI
14	Nitta M, Azuma K, Hata K, Takahashi S, Ogiwara K, Tsuka T, Imagawa T, Yokoe I, Osaki T, Minami S and Okamoto Y: Systemic and local injections of lupeol inhibit tumor growth in a melanoma-bearing mouse model. Biomed Rep. 1:641–645. 2013.PubMed/NCBI
15	Hata K, Hori K, Mukaiyama T, Sakamoto K and Takahashi S: Activators of melanin biosynthesis from Lactuca indica. Nat Med. 57:238–241. 2003.
16	Radzi R, Osaki T, Tsuka T, Imagawa T, Minami S, Nakayama Y and Okamoto Y: Photodynamic hyperthermal therapy with indocyanine green (ICG) induces apoptosis and cell cycle arrest in B16F10 murine melanoma cells. J Vet Med Sci. 74:545–551. 2012. View Article : Google Scholar : PubMed/NCBI
17	Radzi R, Osaki T, Tsuka T, Imagawa T, Minami S and Okamoto Y: Morphological study in B16F10 murine melanoma cells after photodynamic hyperthermal therapy with indocyanine green (ICG). J Vet Med Sci. 74:465–472. 2012. View Article : Google Scholar : PubMed/NCBI
18	Onoyama M, Tsuka T, Imagawa T, Osaki T, Minami S, Azuma K, Kawashima K, Ishi H, Takayama T, Ogawa N and Okamoto Y: Photodynamic hyperthermal chemotherapy with indocyanine green: a novel cancer therapy for 16 cases of malignant soft tissue sarcoma. J Vet Sci. 15:117–123. 2014. View Article : Google Scholar : PubMed/NCBI
19	Onoyama M, Azuma K, Tsuka T, Imagawa T, Osaki T, Minami S, Ogawa N and Okamoto Y: Effects of photodynamic hyperthermal therapy with indocyanine green on tumor growth in a colon 26 tumor-bearing mouse model. Oncol Lett. 7:1147–1150. 2014.PubMed/NCBI
20	MacEwen EG, Patnaik AK, Harvey HJ, et al: Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest. 4:397–402. 1986. View Article : Google Scholar : PubMed/NCBI
21	Theon AP, Rodriguez C and Madewell BR: Analysis of prognostic factors and patterns of failure in dogs with malignant oral tumors treated with megavoltage irradiation. J Am Vet Med Assoc. 210:778–784. 1997.PubMed/NCBI
22	Boria PA, Murry DJ, Bennett PF, Glickman NW, Snyder PW, Merke BL, Schlittler DL, Mutsaers AJ, Thomas RM and Knapp DW: Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. J Am Vet Med Assoc. 224:388–394. 2004. View Article : Google Scholar : PubMed/NCBI